<DOC>
	<DOC>NCT01447069</DOC>
	<brief_summary>The purpose of this study is to determine whether Salbutamol is effective in the treatment of severe heart failure due to ischemic and non- ischemic cardiomyopathy.</brief_summary>
	<brief_title>Use of Beta-agonists in Stable Severe Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Ambulatory Patients with a diagnosis of ischemic and nonischemic cardiomyopathy with a measured EF &lt;35%, class III as defined by the NYHA with ICD and who receive optimal pharmacological therapy. Heart Failure class I, II, IV atrial fibrillation any significant valvular disease chronic obstructive pulmonary disease who treated with inhaled Î²2 agonist significant kidney disease with eGFR &lt;30% severe uncontrolled electrolyte abnormalities prior allergic reaction to Salbutamol Pregnancy and nursing women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>heart failure stage 3</keyword>
	<keyword>beta 2 agonist</keyword>
	<keyword>N-terminal pro-brain natriuretic peptide</keyword>
	<keyword>ejection fraction &lt;35%</keyword>
</DOC>